Posted by AGORACOM-JC
at 4:26 PM on Thursday, April 4th, 2019
WHY NORTHBUD FARMS?
Canadian regulatory door for CIP (Cannabinoid Infused Products) is opening this year as shown in other legal jurisdictions (Colorado, Washington, Nevada, California)
Infused products sector has become the highest margin segment of the industry
Positioned to be a raw input producer for this space
Currently working with multiple food, beverage and science companies to provide safe standardized cannabinoid infused raw inputs for large scale GMP manufacturing of products
NORTHBUD Signs Binding Letter of Intent to Enter U.S. Market
with Strategic Acquisition of Multi-State Licensed Operator Eureka Vapor
CHECK OUT OUR RECENT INTERVIEW
FULL DISCLOSURE: NORTHBUD is an advertising client of AGORA Internet Relations Corp.
Posted by AGORACOM-JC
at 4:29 PM on Monday, April 1st, 2019
Announced that its first 10,000 square foot cultivation facility in Oroville, WA will be occupied by a Tier-3, I-502 tenant starting June 01, 2019.
Tenant is currently in the process of obtaining occupancy approval from the Washington State Liquor and Cannabis Board to begin planting the Tenant’s crop for the season.
In addition to the 10,000 sq. ft. space, Tenant is planning to plant a 20,000 sq. ft. out-door crop. The Tenant is licensed to build out up to 30,000 square feet on the existing property in Oroville, WA.
VANCOUVER, British Columbia, April 01, 2019 – BOUGAINVILLE VENTURES INC. (“Bougainville” or the “Company”) (CSE: BOG), providing cannabis infrastructure and seed-to-sale services to I-502 tenant-growers, is pleased to announce that its first 10,000 square foot cultivation facility in Oroville, WA will be occupied by a Tier-3, I-502 tenant (the “Tenantâ€) starting June 01, 2019. The Tenant is currently in the process of obtaining occupancy approval from the Washington State Liquor and Cannabis Board (WSLCB) to begin planting the Tenant’s crop for the season. In addition to the 10,000 sq. ft. space the Tenant is planning to plant a 20,000 sq. ft. out-door crop. The Tenant is licensed to build out up to 30,000 square feet on the existing property in Oroville, WA.
CEO, Andy Jagpal Comments: “We are excited to
see our first Tier-3, I-502 tenant move forward towards a successful
growing season. This first planting season signals a new phase for
Bougainville concept of providing fully built out turnkey facilities to
cannabis growers and processors.These facilities remove financial
barriers for cannabis cultivators as traditional funding can be limited.
In addition, steps are being taken to get a second tenant up and
running for the 2019 growing season. We are moving towards our goal of
revenue generating self-sufficiency.â€
About the Washington I-502 Marijuana Market In November 2012, the Washington State Liquor Control Board (WSLCB) passed Initiative 502 (I-502) pursuant to a vote by the people of the State of Washington. I-502 authorized the WSLCB to regulate and tax recreational marijuana products for persons over twenty-one years of age and thereby created a new industry for growing, processing and selling of Washington State-regulated recreational marijuana products. A recent WSLCB commissioned report by the Rand organization suggests that there are currently up to 650,000 recreational marijuana users in Washington State, worth approximately $1.25 – $1.5 billion USD in annual sales.Â
About Bougainville Ventures, Inc. Bougainville provides cannabis infrastructure and seed-to-sale services to I-502 tenant-growers leasing greenhouse facilities space and providing fully built-out, turnkey solutions and ancillary services including processing, cannabis expertise and marketing and sales resources. Greenhouse canopies provide a 50% saving in cultivation cost. Bougainville has 10,000 sq.ft., in near production in Oroville, WA, sufficient land for two more pods of the same size.
Posted by AGORACOM-JC
at 11:43 AM on Monday, April 1st, 2019
SPONSOR: North Bud Farms Inc. (NBUD:CSE) Sustainable low cost, high
quality cannabinoid production and procurement focusing on both
bio-pharmaceutical development and Cannabinoid Infused Products. Click Here For More Information
NBUD: CSE
—————
CBD oil shortage continues as marijuana producers scramble to meet demand
“The popularity of CBD oil and CBD in general has far exceeded our expectations,” said Ray Gracewood, chief commercial officer of OrganiGram, a licensed producer based in Moncton, N.B.
“To this point, CBD oil is the biggest surprise from an adult recreational perspective, and has got the potential to be a huge product within that channel.”
Carolyn Ray · CBC News
CBD oil has been touted as a solution to everything from ways to limit
human anxiety to pet medicine. (David Zalubowski/Associated Press)
Mona Scott was one of the first people to line up at a marijuana
store in Nova Scotia on the first day of recreational legalization,
eager to get her hands on a type of non-impairing cannabis extract after
hearing about its medicinal benefits.
But she quickly discovered there was no CBD oil in stock that day in
October, nor have there been any bottles in the 10 times since that
she’s visited the Nova Scotia Liquor Corp. store in Truro, N.S.
“The last time I went in was about the first week of December when
the guy walked over to me and said, ‘We don’t have any and we’re not
going to have any for six months,'” said Scott, who sought out the oil
to treat her anxiety.
Pure CBD oil doesn’t make the user high because it does not contain
THC, or tetrahydrocannabinol. While research on the benefits of CBD oil
has been limited, it has surged in popularity as a treatment for medical issues including pain, seizures and nausea.
Demand ‘far exceeded’ expectations
Scott is one of a long list of Nova Scotians who have caused a huge
surge in demand for the product, something one licensed producer said
has caught them completely off guard.
“The popularity of CBD oil and CBD in general has far exceeded our
expectations,” said Ray Gracewood, chief commercial officer of
OrganiGram, a licensed producer based in Moncton, N.B.
“To this point, CBD oil is the biggest surprise from an adult
recreational perspective, and has got the potential to be a huge product
within that channel.”
So far, OrganiGram is the only company that has been able to provide
any supply to the NSLC, said a spokesperson from the Crown corporation.
“We currently have products containing up to 20 per cent CBD but not
the pure CBD oil,” said Beverley Ware. “Every province is in the same
situation.”
At this point, no producers have even given them a timeframe for when it may be available for purchase.
The NSLC said no producers have been able to give them a timeframe for
when pure CBD oil will be back in stock. (Paul Palmeter/CBC)
Gracewood said OrganiGram has been reserving its supply for its
medical patients, who have not experienced a shortage in their
medicine.
The company is now shifting its production to try to fill the gap for
retail stores. Gracewood said they have orders from one end of the
country to the other.
“It represents almost half of our business now,” he said of their
medical business. He said because no producer has been able to make
enough oil to fill the demand in the recreational market, the company is
still relying on estimates as to how much they need to produce.
“The reality of the production environment is that cannabis takes a
certain amount of time to grow within our facility and therefore it
takes us some time to adapt to changes within forecasting.”
Oil from hemp
The demand in oil also has OrganiGram pushing to create new
partnerships with hemp farms, as CBD can derive from both cannabis and
hemp.
“This entire industry is completely new and there’s no way that
anybody could have forecasted all the variables, whether it’s the
attractiveness of CBD oil, or the demand for pre-rolls or the balance
between dried flower and cannabis oil,” Gracewood said.
OrganiGram is facing a class-action lawsuit
over cannabis that was tainted with unapproved pesticides in 2016.
Gracewood wouldn’t comment on whether the case was affecting their
production.
In the meantime, Scott has started advocating to change
marijuana laws. She started to order pure CBD oil from the United
States. While she received the first few bottles, other orders have
since been seized at the border.
She said if Canadian producers can’t fill the void, she should be able to order from other countries.
“For Canada to open up with legalization and to no have it to offer people, I was quite shocked by that.”
Tags: Hemp, stocks, THC, tsx, tsx-v Posted in All Recent Posts, Featured, North Bud Farms Inc | Comments Off on North Bud Farms Inc. $NBUD.ca – CBD oil shortage continues as marijuana producers scramble to meet demand $WEED.ca $CGC $ACB $APH $CRON.ca $HEXO.ca $TRST.ca $OGI.ca
Posted by AGORACOM-JC
at 9:17 AM on Monday, April 1st, 2019
Announced that they are currently in negotiations with several cannabinoid extraction companies in Oregon, regarding the acquisition of the joint venture’s hemp biomass produced at the Scio farm from the 2018 harvest.
The team at the Scio farm has prepared processing samples ranging in size from 100 lbs to 2,000 lbs. for the extraction companies
Escondido, California–(April 1, 2019) – MARIJUANA COMPANY OF AMERICA INC. (OTCQB: MCOA) (“MCOA” or the “Company“), an innovative hemp and cannabis corporation, and its Joint Venture partner Global Hemp Group (CSE: GHG) (OTC: GBHPF) (FSE: GHG) (together with the Company, the “Partners“) are pleased to announce that they are currently in negotiations with several cannabinoid extraction companies in Oregon, USA, regarding the acquisition of the joint venture’s hemp biomass produced at the Scio farm from the 2018 harvest. The team at the Scio farm has prepared processing samples ranging in size from 100 lbs to 2,000 lbs. for the extraction companies. The biomass is being processed into CBD crude oil with the option to refine it further into isolate, or full spectrum oil, in order to increase its value on the market. Results from the current extraction test batches are expected to be received by mid-April and will serve as a basis for the final terms of the sale of the biomass by the Partners.
Cloning Update
The cloning process is well underway at the Scio farm. For this
year’s cultivation, four different strains have been chosen from the
latest high CBD industrial hemp varieties, which are being used as a
base for the in-house propagation program. The goal of the program is to
produce approximately 50,000 clones to populate the lower 35 acres of
the Scio farm for the 2019 season, and reduce and/or eliminate the need
for the acquisition of any additional seeds or clones from outside
sources. The program started with 400 high quality plants. Through a
regimen of proper nutrients and a controlled environment, these “mother”
plants will grow into very large bushes, which will be used to derive a
sufficient number of clones, ensuring that the target number of plants
required for this year’s cultivation is reached. Once removed from the
mother plants, the clones will then be placed in a propagation
greenhouse to root. Once rooted and well established, the clones will
then be ready to be planted in the fields, which is expected to begin
this year in late May or early June.
Expansion in 2019
The Company continues to evaluate a number of opportunities to expand
the scope of its project in Oregon. As previously announced, a number
of local farmers are interested in working with the joint venture
partners to grow hemp in 2019. The Oregon Department of Agriculture
expects hemp cultivation in Oregon to grow from 11,514 acres in 2018 to
more than 25,000 in this current year. In order for new hemp farmers to
be successful, they will need to rely on experienced hemp farming teams
like our Scio farm team. This will create potential opportunity to joint
venture with the local farming community.
Micropropagation (Tissue Culture)
The Company has begun preliminary exploration to expand its business
into micropropagation of hemp plants. By focusing on culturing the
tissue from feminized “mother” hemp plants that are proven to produce
high CBD levels, the Company believes it can more efficiently provide
plants with higher-yielding and more profitable CBD content.
Micropropagation techniques rely on uniform tissue sampling from high
yielding CBD feminized hemp plants, that is more effective than
developing plants from the more traditional methods of germination from
seed or cloning from other plants.
About Marijuana Company of America, Inc.
MCOA is a corporation which participates in: (1) product research and
development of legal hemp-based consumer products under the brand name
“hempSMART™”, that targets general health and well-being; (2) an
affiliate marketing program to promote and sell its legal hemp-based
consumer products containing CBD; (3) leasing of real property to
separate business entities engaged in the growth and sale of cannabis in
those states and jurisdictions where cannabis has been legalized and
properly regulated for medicinal and recreational use; and, (4) the
expansion of its business into ancillary areas of the legalized cannabis
and hemp industry, as the legalized markets and opportunities in this
segment mature and develop.
About Our hempSMART Products Containing CBD
The
United States Food and Drug Administration (FDA) has not recognized CBD
as a safe and effective drug for any indication. Our products
containing CBD derived from industrial hemp are not marketed or sold
based upon claims that their use is safe and effective treatment for any
medical condition as drugs or dietary supplements subject to the FDA’s
jurisdiction.
About Global Hemp Group Inc.
Global Hemp Group Inc. (CSE: GHG) (OTC: GBHPF) (FSE: GHG), is focused
on a multi-phased strategy to build a strong presence in the industrial
hemp industry in both Canada and the United States. The Company is
headquartered in Vancouver, British Columbia, with hemp cultivation
operations in New Brunswick and Oregon. The first phase of this strategy
is to develop hemp cultivation with the objective of extracting
cannabinoids (CBD, CBG, CBN & CBC) and creating a near term revenue
stream that will allow the Company to expand and develop successive
phases of the strategy. The second phase of the plan will focus on the
development of value-added industrial hemp products utilizing the
processing of the whole hemp plant, as envisioned in the Company’s Hemp
Agro-Industrial Zone (HAIZ) strategy
Forward Looking Statements
This news release contains “forward-looking statements” which are
not purely historical and may include any statements regarding beliefs,
plans, expectations or intentions regarding the future. Such
forward-looking statements include, among other things, the development,
costs and results of new business opportunities and words such as
“anticipate”, “seek”, intend”, “believe”, “estimate”, “expect”,
“project”, “plan”, or similar phrases may be deemed “forward-looking
statements” within the meaning of the Private Securities Litigation
Reform Act of 1995. Actual results could differ from those projected in
any forward-looking statements due to numerous factors. Such factors
include, among others, the inherent uncertainties associated with new
projects, the future U.S. and global economies, the impact of
competition, and the Company’s reliance on existing regulations
regarding the use and development of cannabis-based products. These
forward-looking statements are made as of the date of this news release,
and we assume no obligation to update the forward-looking statements,
or to update the reasons why actual results could differ from those
projected in the forward-looking statements. Although we believe that
any beliefs, plans, expectations and intentions contained in this press
release are reasonable, there can be no assurance that any such beliefs,
plans, expectations or intentions will prove to be accurate. Investors
should consult all of the information set forth herein and should also
refer to the risk factors disclosure outlined in our annual report on
Form 10-12G, our quarterly reports on Form 10-Q and other periodic
reports filed from time-to-time with the Securities and Exchange
Commission. For more information, please visit www.sec.gov.
For more information, please visit the Company’s websites at:
Tags: CBD, marijauana, THC, tsx Posted in Marijuana Company of America | Comments Off on Marijuana Company of America $MCOA Provides Update on Processing of Hemp from Oregon Joint Venture $AERO $CBDS $CGRW $APH.ca $GBLX $ACG $ACB $WEED.ca $HIP.ca
Posted by AGORACOM-JC
at 3:51 PM on Wednesday, January 30th, 2019
WHY NORTHBUD FARMS?
Canadian regulatory door for CIP (Cannabinoid Infused Products) is opening this year As shown in other legal jurisdictions (Colorado, Washington, Nevada, California)
Infused products sector has become the highest margin segment of the industry
Positioned to be a raw input producer for this space
Currently working with multiple food,
beverage and science companies to provide safe standardized cannabinoid
infused raw inputs for large scale GMP manufacturing of products
Announced Creation of “1017†Distribution and Signing of a LOI to Acquire Janey’s Cannabis Line
THE OPPORTUNITY
Acquired late stage ACMPR applicant GrowPros MMP from Tetra Bio-Pharma (TSXV: TBP)
GrowPros MMP application was submitted in November 2014 and is currently in the ‘Confirmation of Readiness’ stage.
Announced the amendment of its licence application to add 500K SQ. FT. of outdoor cultivation area
Posted by AGORACOM-JC
at 3:11 PM on Thursday, January 10th, 2019
SPONSOR: North Bud Farms Inc. (NBUD:CSE) Sustainable low cost, high
quality cannabinoid production and procurement focusing on both
bio-pharmaceutical development and Cannabinoid Infused Products. Click Here For More Information
Marijuana is going mainstream and Wall Street has started to notice. Recreational marijuana is now legal in Canada.
And even though there is still a federal ban on pot in the United States, Washington has started to loosen some regulations on other products derived from cannabis, including hemp, following the recent passage of the Farm Bill.
New York (CNN Business)Marijuana is going mainstream and Wall Street has started to notice. Recreational marijuana is now legal in Canada. And even though there is still a federal ban on pot in the United States, Washington has started to loosen some regulations on other products derived from cannabis, including hemp, following the recent passage of the Farm Bill.
Several states have also legalized recreational and medical marijuana. That’s why Vivien Azer of Cowen & Co. is extremely bullish about the prospects for cannabis companies. Â
Azer is the first analyst at a major stock research firm to start coverage of cannabis companies. She held a call with reporters on Tuesday to discuss her views on the sector. Azer covers Canada’s Canopy Growth (CGC) and Tilray (TLRY) as well as US-based cannabis packaging maker KushCo (KSHB). Â She now thinks the market for cannabis in the United States will reach $80 billion by 2030. That sales potential has already attracted the interest of several alcoholic beverage and tobacco giants seeking growth as booze and cigarette sales slump. Â
Azer expects more deals like this, particularly from the beverage makers. The rationale: Drink companies view cannabis as a product that could lessen demand for beer, wine and hard alcohol, particularly as more US states legalize marijuana. Â “Consumers say they cut back on alcohol when they mix alcohol and cannabis,” Azer said during the conference call Tuesday, adding that she would not be surprised to see Diageo (DEO), the maker of Johnnie Walker, Ketel One and Guinness, to eventually make a deal to get into the cannabis market along with other spirits companies. Â
Although Azer is predicting strong demand for legal cannabis in Canada, the United States and other parts of the world, she still thinks that many of the pot stocks got ahead of themselves leading up to the legalization of marijuana in Canada in October — and that is why many of them have fallen in the past few months. Â
She added that some dispensaries in Canada were faced with shortages of marijuana and also couldn’t handle demand for online orders. Some were forced to delay shipments. That’s led to some choppy sales in the first few weeks since legalization. Â “It comes down to fundamentals. So is it surprising to see the cannabis stocks sell off after Canada’s legalization? No. The runup was too far too fast and there were some companies that reported revenue misses,” Azer said. Â
A worker collects cuttings from a marijuana plant at the Canopy Growth Corporation facility in Smiths Falls, Ontario. Â Azer concedes that the stocks may remain volatile for a bit because they have attracted so much interest from more fickle individual investors, as opposed to big institutions like mutual funds and hedge funds. Â
But she argues that the stocks will stabilize once more long-term investors join some of the short-term traders and start buying them. That might happen sooner rather than later as Wall Street recognizes that marijuana is becoming a legitimate consumer product. Â
Piper Jaffray initiated coverage on Canopy and Tilray on Wednesday with outperform ratings. Canadian companies Aurora (ACB) and Aphria (APHA) have recently begun listing in the US, too, which means analysts may begin covering them as well. Â Source: https://www.cnn.com/2019/01/09/investing/cannabis-stocks-canopy-tilray-alcohol-tobacco-cowen/index.html
Posted by AGORACOM-JC
at 10:30 AM on Monday, December 10th, 2018
SPONSOR: Bougainville Ventures Inc (CSE: BOG) Converting irrigated farmland to greenhouse-equipped farmland. Bougainville does not “touch the plant†and only provides agricultural infrastructure as a landlord for licensed marijuana growers.
————————–
While marijuana stocks have pulled back with the chaos of the broader
markets in late 2018, we cannot forget about the countless catalysts
that are still out there.
One of the major catalysts involves mergers and acquisitions.
Alcohol companies have had significant interest, for example.
Months ago, Constellation Brands increased its stake in Canopy Growth (CGC) by $4 billion.
That came just months after Constellation first took a 10% stake in
Canopy to help create nonalcoholic cannabis-infused drinks and other
products.
All, as sales of beer fall in the United States,
brewers have begun to bet that legalization of marijuana around the
globe, especially the United States, will continue to build momentum and
sales of cannabis products will take off.
Molson Coors even
listed legal cannabis among the biggest possible risks to its business
in its annual shareholder report. Even Coca-Cola expressed some interest
at one point.
Now, cigarette makers are jumping into the fray, too.
For example, shares of Cronos (CRON) rocketed higher last
week on news that Altria Inc. took at 45% stake in the company for $1.8
billion.
“Investing in Cronos Group as our exclusive partner in
the emerging global cannabis category represents an exciting new growth
opportunity for Altria,” said Howard Willard, Altria’s CEO, as quoted by
CNN.
Talks started, as the tobacco industry comes under
pressure, as sales have begun to sharply decline. Just last year,
cigarette smoking fell to its lowest point in history. Marijuana sales
may bring back some of that lost revenue, though.
According to
CNBC, “Counting both legal and black-market sales, the total demand for
pot is approximately $52.5 billion, Marijuana Business Daily has
reported.â€
This could potentially lead to other major M&A
deals in the industry following Altria and Constellation news. If
nothing else, such major deals provide further evidence that the
opportunities in the global marijuana industry are much more than just
hype.
For Altria to invest $1.8 billion in a company isn’t small change.
We wouldn’t be shocked to see other pot stocks see further M&A interest moving forward.
Stay tuned for more on potential deals right here.
Tags: Hemp, Marijuana, THC Posted in Bougainville Ventures | Comments Off on Bougainville Ventures (BOG:CSE) – Marijuana M&A: Altria Group Opens the Door to Major Deals $CROP.ca $VP.ca NF.ca $MCOA
Posted by AGORACOM-JC
at 4:18 PM on Thursday, November 22nd, 2018
Construction cannabis production facility in Low, Quebec remains on schedule as per the timeline provided from our builder NGA Construction
Erecting of the steel structure began on the 19th of November and is expected to take approximately 30 days to complete
Company expects the building to be operational in Q1 2019
TORONTO, Nov. 22, 2018 — North Bud Farms Inc. (CSE: NBUD) (“NORTHBUD” or the “Company”) is pleased to provide shareholders with an update on our corporate activities.
Construction of our Cannabis Production Facility in Low, Quebec NORTHBUD is pleased to update shareholders that the construction of our cannabis production facility in Low, Quebec remains on schedule as per the timeline provided from our builder NGA Construction. Erecting of the steel structure began on the 19th of November and is expected to take approximately 30 days to complete. We expect the building to be operational in Q1 2019. Please follow our social media channels for video updates of the facility construction (https://vimeo.com/302330795) and branding out reach.
Cannabis Act Application Migration of the application to the Cannabis Licensing Tracking System (“CLTSâ€) has begun in collaboration with Cannabis Consulting Inc., one of the leading consultancy firms in the industry.
Update on Janey’s Inc. Acquisition NORTHBUD and Janey’s continue to work on finalizing the acquisition agreement to include additional product segments. To date Janey’s has fulfilled multiple orders to the Ontario Cannabis Store and intends to expand its offering in the upcoming product calls.
Corporate Initiatives NORTHBUD wishes to inform shareholders that its Board of Directors has approved management’s request to explore business opportunities in other international jurisdictions.
“This development represents an evolution in our business since going public and we feel it is important to update shareholders and potential shareholders that we will be actively pursuing international opportunities that we believe are complementary to our core business and that should create value for shareholders as we expand NORTHBUD’s global presence,†said Ryan Brown, CEO of North Bud Farms Inc.
About North Bud Farms Inc. North Bud Farms Inc., through its wholly-owned subsidiary GrowPros MMP Inc. which was acquired in February 2018, is pursuing a license under the Access to Cannabis for Medical Purposes Regulations (ACMPR).  North Bud Farms will be constructing a state-of-the-art purpose-built cannabis production facility located on 95 acres of Agricultural Land in Low, Quebec. North Bud Farms will be focused on Pharmaceutical and Food Grade cannabinoid production in preparation for the legalization of edibles and ingestible products scheduled for October 2019.
Neither the Canadian Securities Exchange (the “CSEâ€) nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.
Forward-looking statements
Certain statements included in this press release constitute forward-looking information or statements (collectively, “forward-looking statementsâ€), including those identified by the expressions “anticipateâ€, “believeâ€, “planâ€, “estimateâ€, “expectâ€, “intendâ€, “mayâ€, “should†and similar expressions to the extent they relate to the Company or its management. The forward-looking statements are not historical facts but reflect current expectations regarding future results or events. This press release contains forward- looking statements. These forward-looking statements are based on current expectations and various estimates, factors and assumptions and involve known and unknown risks, uncertainties and other factors. Such risks and uncertainties include, among others, the risk factors included in North Bud Farms’ final long form prospectus dated August 21, 2018 which is available under the issuer’s SEDAR profile at www.sedar.com.
FOR ADDITIONAL INFORMATION, PLEASE CONTACT:
North Bud Farms Inc.
Edward Miller
VP, IR & Communications
Office: (855) 628-3420 ext. 3 [email protected]
Posted by AGORACOM-JC
at 9:18 AM on Tuesday, November 20th, 2018
Company takes a significant step forward to become a fully integrated drug development company
enables the company to produce cannabis and cannabinoid drug products for Tetra’s and Panag Pharma’s development activities including the ocular drug formulations
Quantum Pharma owned by Dr. Peter Ford was the GMP manufacturing division of Ford’s Family Pharmacy and Wellness Centre
ORLEANS, Ontario, Nov. 20, 2018 — Tetra Bio-Pharma Inc.(“Tetra†or “TBPâ€), (TSX VENTURE: TBP) (OTCQB: TBPMF), and Quantum Pharma Inc. (“Quantumâ€) today announced the signing of a binding proposal (the “Proposal“) for exclusive access to a Health Canada licensed facility (i.e., Drug Establishment License; DEL) that enables the company to produce cannabis and cannabinoid drug products for Tetra’s and Panag Pharma’s development activities including the ocular drug formulations.  Quantum Pharma owned by Dr. Peter Ford was the GMP manufacturing division of Ford’s Family Pharmacy and Wellness Centre. Their formulation expertise will enable Tetra to develop innovative products for future clinical trials.Â
The Proposed Transaction is expected to provide Tetra with:
Exclusive access to a Health Canada licensed facility (DEL) to fabricate cannabis and cannabinoid drug products for Tetra and Panag’s development activities;
Cannabis and cannabinoid drug product formulation expertise; and
The ability to manufacture products for all its clinical trials and commercial launches.
Dr. Guy Chamberland, CEO and CSO of Tetra Bio-Pharma stated, “We are very pleased to announce this important development to our shareholders. We have been working with Ford’s Family Pharmacy and Wellness Centre since 2016. Dr. Peter Ford and his team have created several innovative formulations and instruments for the fabrication of Tetra’s prescription drugs. This exclusive agreement not only secures the innovations and production know-how developed for Tetra, but also protects these assets from an acquisition by a competitor. Quantum Pharma will be an exclusive partner to Tetra and Panag enabling us to execute our future planned trials as well as prepare for our product launches.â€
Dr. Chamberland further stated, “Tetra has already entered into various agreements to ensure the supply meets the demand for cannabis, THC and CBD-based products with partners including Aphria Inc., True North Cannabis, a USA-based synthetic cannabinoid manufacturer and a phytocannabinoid supplier. With the expected completion of the Panag acquisition, Tetra will become vertically integrated with drug development capabilities that range from discovery all the way through to commercial launch. Our partnerships with Genacol Corporation and Kombucha Baby Brewing Company and its partners provides Tetra with a global sales and distribution platform for the commercialization of OTC drug and wellness products. In addition, Tetra has also established distribution and sales agreements with two pharmaceutical companies for its PPP001 prescription drug product.â€
About Tetra Bio-Pharma
Tetra Bio-Pharma (TSX-V: TBP) (OTCQB: TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and development with a Health Canada approved, and FDA reviewed, clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. The Company has several subsidiaries engaged in the development of an advanced and growing pipeline of Bio Pharmaceuticals, Natural Health and Veterinary Health Products containing cannabis and other medicinal plant-based elements. With patients at the core of what we do, Tetra Bio-Pharma is focused on providing rigorous scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators, physicians and insurance companies.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward-looking statements Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company’s research and development strategies, the successful integration of this acquisition, Â the ability to obtain orphan drug status, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process, the timing of clinical trials, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. While no definitive documentation has yet been signed by the parties and there is no certainty that such documentation will be signed. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.
For further information, please contact Tetra Bio-Pharma Inc.
Robert Bechard
Executive Vice-President Corporate Development and Licensing
Three of the largest cannabis companies reported earnings this week, painting a portrait of a nascent industry enjoying surging demand as recreational pot becomes legalized in more places—but they’re also encountering some growing pains.
Aurora Cannabis said Monday its revenue rose 260% to $29.7 million Canadian dollars (US$22 million). Net income came in at C$105.5 million, up from C$3.56 million a year ago, largely because of unrealized gains on securities.
On Tuesday, Tilray said revenue rose 86% to C$10 million, while its net loss increased to C$19 million from C$1.8 million a year ago, driven largely by an increase in non-cash stock-based compensation charges.
Also on Tuesday, Cronos Group said revenue in the third quarter rose 186% to C$3.8 million, compared with C$1.3 million a year ago. Cronos lost 4 Canadian cents per share.
Both Tilray and Cronos said that the average price of weed per gram declined. Tilray attributed the decline to an increase in bulk sales as a percentage of total revenue.
However, the price of cannabis could increase in the future because demand is beginning to outstrip supply as Canada and many U.S. states have legalized marijuana. Much of the cannabis sales the three companies reported last quarter came from medicinal marijuana.
“Similar to other Canadian LPs, we are facing demand that outstrips supply,†Aurora’s chief corporate officer Cam Battley said during the company’s earnings conference call. “We anticipate this dynamic to continue for some time.â€
Cannabis stocks surged through most of 2018 before encountering a selloff, once pot became legal in Canada, in a classic buy-on-rumor, sell-on-news scenario. Investors appear to be remaining cautious, despite the strong revenue growth last quarter. On Tuesday, Aurora’s stock on the NYSE fell 3.7%, while TIlray fell 1.9% and Cronos fell 1.7%.
